Takeda Pharmaceutical Company Limited (TAK)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
17.47+0.03 (+0.17%)
At close: 4:00PM EST
| Previous close | 17.44 |
| Open | 17.55 |
| Bid | 17.40 x 1800 |
| Ask | 17.47 x 2900 |
| Day's range | 17.06 - 17.55 |
| 52-week range | 12.43 - 20.00 |
| Volume | 3,246,189 |
| Avg. volume | 3,842,667 |
| Market cap | 54.874B |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | 21.53 |
| EPS (TTM) | 0.81 |
| Earnings date | N/A |
| Forward dividend & yield | 0.85 (4.86%) |
| Ex-dividend date | 29 Sep 2020 |
| 1y target est | 22.61 |
- Business Wire
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda has entered into an exclusive agreement with partner Ovid Therapeutics to develop and commercialize the investigational medicine soticlestat.
- Yahoo Finance
Coronavirus update: Merck to produce J&J vaccines; CDC launches vaccine finder
Merck (MRK) is stepping up to help Johnson & Johnson (JNJ) produce its COVID-19 vaccine, which was authorized last weekend.
- PR Newswire
The Children's National Hospital Rare Disease Institute And Takeda Partner To Standardize Care For Patients With Rare Diseases
Children's National Hospital and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the creation of the Rare Disease Clinical Activity Protocols (Rare-CAP) program, which will establish a networked system for the development, dissemination and curation of protocols to help standardize the process of diagnosis and care for patients with rare diseases.
© 2021 Verizon Media. All rights reserved.
